- About Us
- Services & Solutions
- Technologies
- Discovery
- Reagent Materials Generation
- Monoclonal Antibody Discovery
- Bispecific & Multispecific Antibody Generation
- Lead Optimization
- In Vitro Lead Characterization
- In Vivo Lead Characterization
- Other Molecular Modalities
- IND Filing Support
- Protein Sciences
- Antibody Production
- Protein Production
- Protein Characterization
- Protein Sciences
- Mammalian
- Microbial
- mRNA
- Viral Vaccines
- WuXi XDC – Bioconjugation
- Testing
- Sustainability
- Careers
- Investors
- News & Resources
WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- SustainabilityAbout Us
- CareersAbout Us
- InvestorsAbout Us
- News & ResourcesAbout Us
Scientific Poster Download
Poster modified on 17/10/2023
Overcoming the Challenges in Asymmetric Bispecific Antibody Production by Using Quick’n Clean Platform
Gaozhan Zhang, Lupeng Cui, Dawei Zhang, Mengjie Lu, Jiansheng Wu
WuXi Biologics, NO.240 Hedan Road, Pudong New District, Shanghai, China
Bispecific antibody (BsAb) is a large family of molecules designed to recognize two different epitopes or antigens and represents a highly promising class of biotherapeutic modality. Unlike vanilla antibody, great production challenges with respect to the quantity, quality, and stability of bispecific antibodies have hampered their wider clinical application and acceptance. To support our clients and to overcome the challenges associates with BsAb production, WuXi Biologics has established one HTP BsAb production platform “Quick’n Clean”
This scientific poster was originally presented during the PEGS Boston 2023 conference
Discuss This Poster
To discuss the data in this poster, please complete the form on the following page to connect with our experts.